

SUPPLEMENTARY TABLES

Supplementary Table 1. Baseline characteristics of cases and controls.

	Controls (N = 71,500)	Cases (N = 715)	P-value
Demographics			
Gender male (%)	43,000 (60.14%)	430 (60.14%)	1.0000
Age (Mean ± SD)	69.28 ± 14.31	68.98 ± 13.53	0.5770
Living area			
Urban Area	35,054 (49.12%)	330 (46.15%)	0.0007
Metro Area	17,752 (24.88%)	155 (21.68%)	
Suburban Area	12,118 (16.98%)	140 (19.58%)	
Countryside Area	6,438 (9.02%)	90 (12.59%)	
Insurance premium level			
Dependent	9,387 (13.15%)	57 (7.97%)	<.0001
(\$1-\$19,999)	16,348 (22.91%)	160 (22.38%)	
(\$20,000-\$39,999)	28,251 (39.59%)	344 (48.11%)	
(≥ \$40,000)	17,376 (24.35%)	154 (21.54%)	
Pre-existing comorbidities			
Acute myocardial infarction	163 (0.23%)	8 (1.12%)	<.0001
Congestive heart failure	956 (1.34%)	60 (8.39%)	<.0001
Peripheral vascular disorder	917 (1.28%)	19 (2.66%)	0.0012
Cerebrovascular disease	4,305 (6.02%)	80 (11.19%)	<.0001
Dementia	1,344 (1.88%)	18 (2.52%)	0.2122
Chronic pulmonary disease	2,998 (4.19%)	56 (7.83%)	<.0001
Rheumatologic disease	468 (0.65%)	7 (0.98%)	0.2855
Peptic ulcer disease	5,894 (8.24%)	79 (11.05%)	0.0067
Mild liver disease	4,817 (6.74%)	73 (10.21%)	0.0002
Diabetes without chronic complications	9,114 (12.75%)	151 (21.12%)	<.0001
Diabetes with chronic complications	2,206 (3.09%)	45 (6.29%)	<.0001
Hemiplegia or paraplegia	458 (0.64%)	9 (1.26%)	0.0402
Renal disease	1,709 (2.39%)	60 (8.39%)	<.0001
Any malignancy	2,624 (3.67%)	35 (4.90%)	0.0835
Moderate or severe liver disease	93 (0.13%)	0.00 (0.00%)	0.3346
Neurologic disorder	1,309 (1.83%)	18 (2.52%)	0.1737
Psychiatric disorder	5,649 (7.9%)	79 (11.05%)	0.0019
Angina	6,31 (0.88%)	31 (4.34%)	<.0001
Other ischemic heart disease	1,727 (2.42%)	85 (11.89%)	<.0001
Cardiac valve disease	745 (1.04%)	42 (5.87%)	<.0001
Hypertension	19,637 (27.46%)	360 (50.35%)	<.0001
Hyperlipidaemia	9,917 (13.87%)	152 (21.26%)	<.0001

Percutaneous transluminal coronary angioplasty	125 (0.17%)	10 (1.40%)	<.0001
Health care utilization			
Number of outpatient visit	14.31 ± 15.8	23.03 ± 16.34	<.0001
Number of emergency department visit	0.23 ± 0.78	1.05 ± 1.53	<.0001
Number of hospitalizations	0.15 ± 0.64	1.07 ± 1.28	<.0001
Medication use			
NSAIDs	18,572 (25.97%)	256 (35.8%)	<.0001
Aspirins	6,802 (9.51%)	182 (25.45%)	<.0001
Systemic corticosteroids	5,884 (8.23%)	78 (10.91%)	0.0096
DMARDs	578 (0.81%)	9 (1.26%)	0.182
Beta-blocker	6,761 (9.46%)	173 (24.20%)	<.0001
ACE-inhibitors/ARB	4,274 (5.98%)	99 (13.85%)	<.0001
Calcium-channel blocker	14,527 (20.32%)	282 (39.44%)	<.0001
Statin	6,514 (9.11%)	109 (15.24%)	<.0001
Nicorandil	206 (0.29%)	39 (5.45%)	<.0001
Nitrate	782 (1.09%)	91 (12.73%)	<.0001
Scoring differences			
Charlson comorbidity score (Median, 25–75th)	0 (0–0)	0 (0–1)	<.0001
CHA2DS2-VASc Score (Median, 25–75th)	2 (1–3)	2 (1–4)	<.0001

Abbreviation: DMARD: disease-modifying antirheumatic drugs.

Supplementary Table 2. The risks of AF in different risk groups.

	Nicorandil vs. Nitrate users risk ratio (95% C.I.)	Additive Interaction <i>P</i> -value
Age		
Age > 65 years	1.23 (0.71, 2.13)	
Age ≤ 65 years	3.61 (1.58, 8.22)	0.01
Gender		
Male	1.37 (0.77, 2.45)	
Female	2.28 (1.12, 4.67)	0.73
Cardiovascular disease (MI, CHF, PVD, CVA)		
Presence	1.28 (0.58, 2.83)	
Absence	1.71 (1.10, 2.68)	0.58
Severity		
CHA2DS2-VASc 0-2	2.63 (1.29, 5.37)	
CHA2DS2-VASc 0-2	3.49 (1.13, 10.75)	0.97
CHA2DS2-VASc 6-10	3.49 (1.13, 10.75)	